Effect of micronized progesterone on bone turnover in postmenopausal women on estrogen replacement therapy

Endocrine Research

Volumn 29, Issue 2, 2003, Pages 133-140

  Azizi, G ^a   Hansen, A ^b   Prestwood, K M ^b  

^a Hanover Medical Specialists PA   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Bone alkaline phosphatase; Bone turnover; C terminal telopeptides of type I collagen; Micronized progesterone; N telopeptides of type I collagen; N terminal procollagen peptides

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CHOLESTEROL; COLLAGEN TYPE 1; ESTRADIOL; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOFLAVONE DERIVATIVE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; PROCOLLAGEN; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; TRIACYLGLYCEROL;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD ANALYSIS; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HEADACHE; HEART PROTECTION; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYSTERECTOMY; LIPID ANALYSIS; LONG TERM CARE; LUTEAL PHASE; NAUSEA; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN CROSS LINKING; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS;

AGED; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; CHOLESTEROL; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPOPROTEINS, HDL; OSTEOCALCIN; PEPTIDE FRAGMENTS; POSTMENOPAUSE; PROCOLLAGEN; PROGESTERONE; SEX HORMONE-BINDING GLOBULIN;

EID: 0038683742     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.1081/ERC-120022294     Document Type: Article

References (20)

1. McAuley JW, Kroboth FJ, Kroboth PD. Oral administration of micronized progesterone: a review and more experience. Pharmacotherapy 1996; 16(3):453.
2. Fahraeus L, Larsson-Cohn U, Wallentin L. L-norgestrel and progesterone have different influences on plasma lipoproteins. Eur J Clin Invest 1983; 13(6):447.
3. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273(3):199.
4. de Lignieres B. Oral micronized progesterone. Clin Therap 1999; 21(1):41.
5. Prestwood KM, Kenny AM, Unson C, Kulldorf M. The effect of low dose micronized 17β-estradiol on bone turnover, sex hormones, and side effects in older women: a randomized, double-blind, placebo controlled study. J Clin Endocrinol Metab 2000; 85(12):4462.
6. Ishida Y, Heersche JN. Progesterone stimulates proliferation and differentiation of osteoprogenitor cells in bone cell populations derived from adult female but not from adult male rats. Bone 1997; 20(1):17.
7. Grey A, Cundy T, Evans M, Reid I. Medroxyprogesterone acetate enchances the spinal bone mineral density response to oestrogen in late post-menopausal women. Clin Endocrinol 1996; 44(3):293.
8. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997; 18(4):502.
9. Ikram Z, Dulipsingh L, Prestwood KM. Lack of effect of short-term micronized progesterone on bone turnover in postmenopausal women. J Womens Health Gender-Based Med 1999; 8(7):973.
10. Macnamara P, Loughry HC. Progesterone receptor A and B isoform expression in human osteoblasts. Calcif Tissue Int 1998; 63(1):39.
11. Delmas P. Utility of biochemical markers in osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press, 1996:1075-1085.
12. Prior JC. Progesterone as a bone-trophic hormone. Endocr Rev 1990; 11(2):386.
13. 3, parathyroid hormone, and glucocorticoids. Metabolic Bone Dis Related Res 1984; 5(5):229.
14. Manelli F, Bossoni S, Carpinteri R, Bugari G, Panteghini M, Romanelli G, Giustina A. Sensitivity of bone remodeling markers in elderly male patients chronically treated with glucocorticoids. J Endorcrinol Invest 1999; 22(10 suppl):S79.
15. Wei LL, Leach MW, Miner RS, Demers LM. Evidence for progesterone receptors in human osteoblast-like cells. Biochem Biophys Res Comm 1993; 195(2):525.
16. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988; 241(4861):84.
17. Manzi DL, Pilbeam CC, Raisz LG. The anabolic effect of progesterone on fetal rat calvariae in tissue culture. J Soc Gyn Investig 1994; 1(4):302.
18. Barengolts EI, Kouznetsova T, Segalene A, Lathon P, Odvina C, Kukreja SC, Unterman TG. Effects of progesterone on serum levels of IGF-1 and on femur IGF-1 mRNA in ovariectomized rats. J Bone Miner Res 1996; 11(10):14006.
19. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991; 90(2):171.
20. Moorjani S, Dupont A, Labrie F, De Lignieres B, Cusan L, Dupont P, Mailloux J, Lupien PJ. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991; 73(2):373.